News & Updates

VIDEO: Apalutamide’s tolerability in prostate cancer patients

19 May 2025 by

Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, discusses apalutamide’s tolerability in prostate cancer patients.

VIDEO: Apalutamide’s tolerability in prostate cancer patients

19 May 2025

Management of NSCLC harbouring EGFR exon 20 insertion mutations

16 May 2025 by

Non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertion (exon20ins) mutations is often resistant to approved EGFR tyrosine kinase inhibitors (TKIs). At an industry-sponsored symposium held during the 28^th Congress of the Asian Pacific Society of Respirology, Dr James Ho, Specialist in Respiratory Medicine in Hong Kong, reviewed the biological properties of these mutations and the role of amivantamab, the first EGFR-MET bispecific antibody with proven efficacy in patients with metastatic NSCLC harbouring EGFR exon20ins mutations.

Management of NSCLC harbouring EGFR exon 20 insertion mutations

16 May 2025

Interplay between surgery and pharmacotherapy in multimodality treatment of NSCLC

25 Apr 2025 by

At the 28^th Congress of the Asian Pacific Society of Respirology, Dr Alan Sihoe, Consultant in Cardio-Thoracic Surgery, CUHK Medical Centre, Hong Kong, discussed the interplay between pharmacotherapy and surgery in treatment of non-small-cell lung cancer (NSCLC), and emphasized the importance of immunotherapy (IO) timing for maximizing curative surgery rates. Dr Sihoe also shared a case of a patient with stage IVA NSCLC who received surgery in 2017 followed by two lines of tyrosine kinase inhibitor (TKI) treatment and remained well as of November 2024.

Interplay between surgery and pharmacotherapy in multimodality treatment of NSCLC

25 Apr 2025

Tarlatamab demonstrates durable activity in previously treated SCLC

23 Apr 2025 by

In phase I and II trials, tarlatamab demonstrated promising anticancer activity and a manageable safety profile in heavily pretreated small-cell lung cancer (SCLC) patients – a population with limited treatment options. At an industry-sponsored symposium held during the Immuno-Oncology Hong Kong (IOHK) 2024 conference, Professor Jürgen Wolf of the Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany, presented long-term follow-up data demonstrating tarlatamab’s sustained efficacy and safety, and Dr Herbert Loong of the Department of Clinical Oncology, the Chinese University of Hong Kong, shared local trial participants’ experience with tarlatamab.

Tarlatamab demonstrates durable activity in previously treated SCLC

23 Apr 2025

Clinical insights and updates on use of tislelizumab in advanced ESCC

31 Mar 2025 by

The prognosis of oesophageal squamous cell carcinoma (ESCC) is very poor and treatment options are limited, especially for patients with recurrent or advanced disease. At an industry-sponsored symposium organized by the Hong Kong Society of Clinical Oncology (HKSCO), Professor Beung-Chul Ahn of the National Cancer Centre in Seoul, Korea, presented research data and clinical insights on the use of tislelizumab immunotherapy for advanced ESCC in both second-line and first-line settings.

Clinical insights and updates on use of tislelizumab in advanced ESCC

31 Mar 2025

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

31 Mar 2025 by

Therapeutic advancements based on immuno-oncology (IO) combinations have revolutionized the treatment landscape for renal cell carcinoma (RCC). In particular, front-line use of immune checkpoint inhibitors combined with tyrosine kinase inhibitors (TKIs) offers superior survival benefits compared with TKI monotherapy or IO-IO combinations. At the 10^th Annual Scientific Meeting of the Hong Kong Society of Uro-Oncology (HKSUO) (Uro- Oncology Asia 2025), Professor Viktor Grünwald of the University Hospital Essen, Essen, Germany, presented recent data supporting the broad antitumour activity of pembrolizumab plus lenvatinib in patients with clear- and non-clear-cell RCC histologies.

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

31 Mar 2025

Improvements in PSA, anaemia and performance status with ADT plus ARPI in a patient with mHSPC

28 Mar 2025 by

A 71-year-old male ex-smoker and non-drinker presented with bone pain and back pain in March 2024. He had a past history of advanced squamous-cell carcinoma of the tongue that was managed with surgery and adjuvant chemoradiation in 2018. At presentation, his haemoglobin (Hb) level was 6.3 g/dL, indicating severe anaemia. He also had a raised alkaline phosphatase (ALP) level and a highly elevated prostate-specific antigen (PSA) level of 3,700 ng/mL.

Improvements in PSA, anaemia and performance status with ADT plus ARPI in a patient with mHSPC

28 Mar 2025

Redefining standards in small-cell lung cancer: An Expert interview featuring the clinical challenges in real-world patient cases

24 Mar 2025

In this engaging presentation, renowned Professor Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at Georgetown University (US), shares his Real-world clinical experience in treating extensive-stage small-cell lung cancer and discusses future perspectives on the management of small-cell lung cancer.

Redefining standards in small-cell lung cancer: An Expert interview featuring the clinical challenges in real-world patient cases

24 Mar 2025

Molecular detection of EGFR exon20ins in NSCLC: Why, when and how?

14 Mar 2025 by

Genome-guided therapy has improved survival outcomes and reduced toxicities and complications from cytotoxic chemotherapy, thereby enhancing the quality of life of patients with non-small-cell lung cancer (NSCLC). At an industry-sponsored symposium, Dr Molly Li of the Department of Clinical Oncology, the Chinese University of Hong Kong, and Professor Yoon-La Choi of the Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea, focused on the clinical importance and challenges of detecting EGFR exon 20 insertions (exon20ins) in NSCLC patients and discussed the latest clinical evidence on EGFR exon20ins–targeted treatments.

Molecular detection of EGFR exon20ins in NSCLC: Why, when and how?

14 Mar 2025

Evolving role of alectinib in ALK-positive NSCLC

05 Mar 2025 by

The prognosis of patients with non-small-cell lung cancer (NSCLC) has markedly improved since the identification of oncogenic driver mutations and concomitant discovery of tyrosine-kinase inhibitors (TKIs). At an industry-sponsored meeting during the Immuno-Oncology Hong Kong (IOHK) 2024 conference, Professor Solange Peters of the University of Lausanne in Switzerland shared her insights and experiences in the management of patients with ALK-positive NSCLC and highlighted the importance of considering toxicity profiles when choosing between ALK TKIs.

Evolving role of alectinib in ALK-positive NSCLC

05 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

VIDEO: Apalutamide’s tolerability in prostate cancer patients

VIDEO: Apalutamide’s tolerability in prostate cancer patients

Management of NSCLC harbouring EGFR exon 20 insertion mutations

Management of NSCLC harbouring EGFR exon 20 insertion mutations

Interplay between surgery and pharmacotherapy in multimodality treatment of NSCLC

Interplay between surgery and pharmacotherapy in multimodality treatment of NSCLC

Tarlatamab demonstrates durable activity in previously treated SCLC

Tarlatamab demonstrates durable activity in previously treated SCLC

Clinical insights and updates on use of tislelizumab in advanced ESCC

Clinical insights and updates on use of tislelizumab in advanced ESCC

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

Improvements in PSA, anaemia and performance status with ADT plus ARPI in a patient with mHSPC

Improvements in PSA, anaemia and performance status with ADT plus ARPI in a patient with mHSPC

Redefining standards in small-cell lung cancer: An Expert interview featuring the clinical challenges in real-world patient cases

Redefining standards in small-cell lung cancer: An Expert interview featuring the clinical challenges in real-world patient cases

Molecular detection of EGFR exon20ins in NSCLC: Why, when and how?

Molecular detection of EGFR exon20ins in NSCLC: Why, when and how?

Evolving role of alectinib in ALK-positive NSCLC

Evolving role of alectinib in ALK-positive NSCLC